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Overline: KIDNEY FIBROSIS 
 
One-sentence summary: Elastin-specific MRI allows quantitative and longitudinal renal fibrosis assessment 
and monitoring of treatment efficacy.  
Abstract 
Fibrosis is the common endpoint and currently the best predictor of progression of 
chronic kidney diseases (CKD). Despite several drawbacks, biopsies remain the only 
available means to specifically assess the extent of renal fibrosis. Here we show that 
molecular imaging of the extracellular matrix protein elastin allows for non-invasive 
staging and longitudinal monitoring of renal fibrosis. Elastin was hardly expressed in 
healthy mouse, rat, and human kidneys, whereas it was highly upregulated in cortical, 
medullar, and perivascular regions in progressive CKD. Compared to a clinically relevant 
control contrast agent, the elastin-specific magnetic resonance imaging (MRI) agent 
ESMA specifically detected elastin expression in multiple mouse models of renal fibrosis, 
and also in fibrotic human kidneys. Elastin imaging allowed for repetitive and 
reproducible assessment of renal fibrosis, and it enabled longitudinal monitoring of 
therapeutic interventions, accurately capturing anti-fibrotic therapy effects. Finally, in a 
model of reversible renal injury, elastin imaging detected ensuing fibrosis not identifiable 
via routine assessment of kidney function. Elastin imaging thus has the potential to 




Chronic kidney disease (CKD) has reached pandemic proportions and has become a 
major global medical, societal, and economic burden (1). Renal fibrosis, which is 
characterized by the excessive deposition of extracellular matrix (ECM), is the best 
predictor of progression in CKD. Fibrosis is a common finding in renal biopsies, also in 
patients with partially preserved or restored kidney function. In the clinic, kidney function 
is typically measured via the determination of the glomerular filtration rate (GFR) (2). It is 
well known, however, that the GFR does not accurately reflect the extent of renal fibrosis 
and that the GFR and fibrosis progression do not correlate very well.  
There have been considerable advances in understanding the molecular pathways 
driving renal fibrosis, and more than one hundred pharmacological targets have been 
identified (3); however, translational research has been hampered by the lack of 
diagnostic tools for specific and longitudinal fibrosis staging and treatment monitoring. 
Establishing imaging biomarkers that can be used for specific endpoint analyses in 
clinical trials is instrumental for facilitating the translation of novel therapeutic agents, 
and they can thereby contribute substantially to improving the management of patients 
suffering from renal fibrosis and CKD. 
At present, biopsies are the only available means to specifically diagnose and stage 
renal fibrosis. Needle-based biopsies are invasive, bear the risk of sampling errors, are 
limited in terms of spatial information, and are not suitable for long-term monitoring of 
disease progression or therapy responses (4). Consequently, there is a need for 
alternative, non-invasive, and more informative diagnostic approaches that allow for 
longitudinal staging and monitoring of treatment for renal fibrosis in CKD. 
Alternatives for renal fibrosis assessment include liquid and imaging biomarkers. 
Concerning the former, several serum and urinary biomarkers, such as transforming 
growth factor-β1, connective tissue growth factors and multiple types of collagen have 
been evaluated (5-7). Unfortunately, these liquid biomarkers often only reflect the extent 
of proteinuria, they are not organ-specific enough, and they are typically indicative of 
impaired overall organ function (or inflammatory state), rather than providing specific 
information on the extent, the distribution, or the progression of fibrosis. It is therefore 
not surprising that thus far, these biomarkers have not led to clinically viable options for 
longitudinal staging and treatment monitoring. In recent years, non-invasive imaging has 
received increasing attention as a measure to provide biomarkers for fibrosis 
assessment (8). Functional imaging approaches, such as ultrasound (US) elastography, 
diffusion-weighted and blood oxygen concentration-dependent magnetic resonance 
imaging (MRI), have been proven insufficiently specific to enable accurate diagnosis, 
staging, and treatment monitoring of renal fibrosis (9-13).  
Here, we hypothesized that molecular imaging using an agent that specifically 
recognizes the extracellular matrix (ECM) protein elastin - which is present in much 
lower amounts in healthy kidneys than collagen - may be well-suited for staging and 
treatment monitoring of renal fibrosis. Accordingly, we analyzed elastin expression in 
multiple rodent models with progressive kidney fibrosis and in patients with multiple 
different kidney diseases at various CKD stages. Subsequently, we used the elastin-
specific molecular imaging agent ESMA to non-invasively visualize and quantify fibrosis 
progression, anti-fibrotic therapy responses, and fibrosis-specificity as compared to 
routine renal function parameters.  
 
Results 
Elastin expression in healthy and fibrotic kidneys  
Using immunofluorescence and immunohistochemistry, we analyzed elastin expression 
in healthy and fibrotic mouse, rat, and human kidney samples (Fig. 1 and 2, fig. S1-S3). 
In healthy kidneys in all species, elastin expression was confined to arterial blood 
vessels and focally to the interstitium of the medulla. No expression was observed in the 
cortical interstitium, nor in tubular or glomerular cells (epithelial, endothelial, 
mesenchymal or inflammatory cells). In renal fibrosis, elastin expression was strongly 
upregulated, as evidenced by large electron-dense elastin fibers within and around 
arterial vessels, as well as in the interstitium, intermingled with collagen bundles (Fig. 
1B). A time course analysis of the murine adenine-induced nephropathy model showed 
a progressive upregulation of elastin during disease progression (Fig. 1C). 
Elastin expression during disease progression was subsequently analyzed in 10 mouse 
and rat models of renal fibrosis [unilateral ureteral obstruction (UUO), progressive 
anti-Thy 1.1 mesangioproliferative glomerulonephritis, 5/6 nephrectomy (5/6 Nx), 
ischemia/reperfusion injury (I/R), adenine-diet induced crystal nephropathy, nephrotoxic 
nephritis (NTN), folic acid induced nephropathy (FAN) and genetically induced 
non-inflammatory glomerulonephritis in Col4a3-/- (Alport) mice]. In all models, fibrosis 
development was confirmed by histology and immunohistochemistry using antibodies 
against collagen type I and III and α-SMA (6, 14, 15). In all mouse and rat models, 
pronounced elastin overexpression was found in the medullary and cortical interstitium 
and in perivascular areas (Fig. 1, fig. S2 and S3).  
Time-course analyses in the adenine, I/R, UUO and Alport mouse models revealed 
progressive elastin overexpression, most prominently in the UUO model with up to 
21-fold and 249-fold increases in protein and mRNA amount, respectively (Fig. 1C, fig. 
S3). In line with ultrastructural analyses, fluorescence microscopy showed that elastin 
co-localized with typical components of interstitial fibrotic tissue (fibronectin and collagen 
types I and III), whereas it did not co-localize with basement membrane collagen type IV 
(fig. S4). Furthermore, elastin co-localized with interstitial myofibroblasts (α-SMA+) and 
fibroblasts (PDGFR-β+), suggesting that these cells are key producers of elastin in 
fibrotic kidneys (fig. S4). In agreement with this, when renal fibroblasts were stimulated 
in vitro with classical pro-fibrotic agents, such as platelet-derived growth factor (PDGF)-
BB and PDGF-DD (16), they produced increased amounts of elastin mRNA and protein 
(fig. S5A-E). This was further confirmed by analysis of single-cell RNA sequencing data 
from PDGFR-β-expressing cells isolated from UUO mice (17). Only kidney-resident 
PDGFR-β+/CD45- myofibroblasts were found to express elastin, whereas circulating 
PDGFR-β+/CD45+ myofibroblasts did not express elastin (fig. S5F,G). 
Using immunohistochemistry, Western blot, and qRT-PCR, elastin overexpression was 
verified in renal tissue obtained from CKD patients. Similar to mice and rats, elastin was 
markedly upregulated in renal fibrosis in human tissues (Fig. 2, fig. S6). A prominent 
intimal elastosis of larger arteries (interlobar and arcuate) was confirmed by elastin 
immunohistochemistry, which is in line with arteriosclerotic alterations of the renal 
vasculature (Fig. 2A). When analyzing renal biopsies from 146 patients encompassing 
all major renal diseases (table S1), elastin was found to be significantly overexpressed 
during fibrosis, independent of the underlying disease etiology (Fig. 2D). Furthermore, 
analyses of renal elastin expression in a cohort of patients with immunoglobulin A (IgA) 
nephropathy with different CKD stages indicated that elastin expression was increased 
in early CKD (stage 2) and remained high in more advanced stages (fig. S6B, table S2). 
Control experiments confirmed the specificity of elastin staining (fig. S7). Thus, elastin is 
expressed in low amounts in healthy kidneys in mice, rats, and humans, but is strongly 
upregulated during fibrosis progression, indicating that it may be a suitable target for 
specific molecular imaging of renal fibrosis. 
Molecular imaging of elastin expression in kidney fibrosis 
We next used the elastin-specific MRI contrast agent ESMA to non-invasively visualize 
and quantify renal fibrosis. We previously demonstrated the specificity of ESMA for 
elastin, and showed that it can be used to monitor elastin deposition in atherosclerotic 
plaques (18). In a proof-of-concept study, we also demonstrated that ESMA can be 
employed to detect liver fibrosis (19). ESMA-based molecular imaging of kidney fibrosis 
was initially performed in the I/R and adenine models to optimize the timing of the 
imaging protocol. The routinely used clinical MRI contrast agent gadopentetic acid (Gd-
DTPA) was used as a non-specific control. MRI measurements were performed on a 3T 
clinical scanner before and 2 and 24 h after contrast administration (fig. S8). In 
comparison with pre-contrast scans, optimal normalized signal intensity differences and 
optimal echo time differences were obtained 24 h after contrast administration. We used 
a T1-weighted inversion recovery TFE (turbo field echo) sequence as well as 
T1-weighted TSE (turbo spin echo) imaging (T1WI) and T1 relaxometry measurements. 
As opposed to previous experience with ESMA-based molecular MRI in atherosclerosis 
and liver fibrosis (18, 19), the most suitable modes for kidney fibrosis assessment were 
T1-weighted turbo spin echo imaging with quantification of normalized signal intensities 
and T1 relaxometry acquisition with echo time analysis. Therefore, T1wI and T1 
relaxometry were used in all subsequent experiments (fig. S8). Signal changes were 
normalized to erector spinae muscles and were expressed either as ∆CNR 
(contrast-to-noise ratio) or as ∆R1 (fig. S1). 
We performed ESMA-based MRI experiments in three independent mouse models of 
fibrosis: adenine nephropathy (Fig. 3, fig. S9), I/R (fig. S10) and UUO (fig. S11). T1wI 
revealed significantly higher ESMA accumulation in fibrotic kidneys than in healthy 
kidneys. In addition, in fibrotic kidneys, the accumulation of ESMA was much higher than 
that of untargeted, standard Gd-DTPA (Fig. 3A,B; fig. S9A; S10A,B and S11A,B). 
Quantification of the normalized signal intensities showed an up to 2.8-fold higher 
contrast enhancement for ESMA, in both cortex and medulla in all mouse models 
(Fig. 3C,D; fig. S10C,D and S11C,H). Quantification of MRI echo times obtained using 
T1 relaxometry yielded similar results (fig. S9E,F; S10K,L and S11G).  
After the MRI scans, renal injury and fibrosis development were confirmed by histology 
(fig. S1), and elastin expression by Western blot analysis (fig. S9B,C; S10E,F and S11D) 
as well as fluorescence microscopy (fig. S9D, S10G and S11E), corroborating the 
reproducibility of the mouse models and the measurement techniques used. To further 
validate the findings obtained in the MRI experiments, gadolinium concentrations in 
healthy and fibrotic kidneys were quantified using inductively coupled plasma mass 
spectrometry (ICP-MS) and laser-ablation ICP-MS (LA ICP-MS). Gadolinium 
concentrations closely reflected the normalized MRI signal intensities and echo times, 
with the highest concentrations detectable in fibrotic kidneys in mice that had received 
ESMA (Fig. 3E-G, fig. S10H-J, fig. S11F). 
Ex vivo analysis of human biopsy specimens from healthy and fibrotic kidneys incubated 
with ESMA or Gd-DTPA confirmed specific binding of ESMA to fibrotic kidneys 
(Fig. 3H-L). MRI T1wI signals (Fig. 3I,J) and gadolinium concentration quantification 
(Fig. 3K,L) revealed the highest amounts of contrast agent accumulation in fibrotic 
kidneys after ESMA incubation compared to healthy kidneys and to fibrotic kidneys 
incubated with Gd-DTPA. 
ESMA specificity 
To confirm the specificity of ESMA binding to elastin, we performed an in vivo 
competition experiment in the I/R mouse model using an injection with a 25-fold excess 
of 69Ga-labeled ESMA, which does not alter signal intensities in MRI, followed 4 h later 
by injection of standard 153Gd-ESMA. Mice pre-injected with 69Ga-ESMA for competition 
purposes showed significantly lower MRI signal intensities as compared to mice 
receiving 153Gd-ESMA without pre-blocking, supporting the specificity of ESMA (Fig. 
4A,B). The expression of elastin and other fibrosis markers such as collagen I and α-
SMA confirmed equal presence of renal fibrosis in both groups (Fig. 4C-E). To further 
confirm the specificity of ESMA binding to sites of elastin expression, we incubated 
murine renal tissues ex vivo with radiolabeled 99mTc-ESMA with or without pre-blocking 
followed by microautoradiography analyses. The binding of radioactive 99mTc-ESMA to 
elastin fibers in the vasculature in healthy mouse kidneys, as well as the binding of 
99mTc-ESMA to the interstitially deposited elastin fibers in fibrotic mouse kidneys, could 
be efficiently inhibited upon competitive blocking with non-radioactive 153Gd-ESMA (Fig. 
4F,G). 
Longitudinal monitoring of fibrosis progression 
To assess the ability of ESMA to non-invasively capture disease progression and 
therapy effects, we monitored fibrosis development in the adenine-induced nephropathy 
mouse model over 21 days. The normalized MRI signal intensities corresponded to the 
extent of fibrosis and elastin expression in both cortex and medulla (Fig. 5A-C), 
suggesting that ESMA-based molecular imaging is useful for fibrosis staging. Elastin 
expression was confirmed by Western blot analysis and fluorescence microscopy (Fig. 
5D,E). We also evaluated whether ESMA was completely cleared from the kidney after 
its administration and initial accumulation, to ensure that the imaging procedure can be 
readily repeated. Signal quantification in the cortex and medulla showed a ∆CNR peak 
at 24 h after ESMA injection, and a gradual decrease at 48 and 72 h. About 95% of the 
contrast agent was eliminated from the kidney within 72 h after ESMA administration 
(Fig. 5B,C), indicating that renal fibrosis can be longitudinally and repetitively assessed 
using ESMA-enhanced molecular MRI. 
Imaging of anti-fibrotic treatment response 
We next analyzed the suitability of elastin imaging to monitor treatment responses in the 
adenine nephropathy model (Fig. 6A-G), using daily intraperitoneal administration of the 
inflammasome inhibitor CRID3 (20). Crystal-induced nephropathies are increasingly 
recognized as a major pathogenic mechanism of progressive kidney diseases, and 
inflammasome activation appears to be of central importance in their pathogenesis and 
fibrosis development (21-23). We previously showed that inflammasome inhibition 
reduces renal fibrosis in the adenine nephropathy model (23). Confirming our previous 
findings, CRID3 treatment also attenuated renal fibrosis and significantly reduced elastin 
deposition in the kidney in our adenine model (Fig. 6A,B). Molecular imaging using 
ESMA allowed for non-invasive assessment of therapy responses, as evidenced by 
significantly reduced MRI signal intensities (Fig. 6C,D,F; fig. S12A). In a second 
experimental setup, we treated the I/R mouse model with the receptor tyrosine kinase 
inhibitor imatinib from day 7 to day 21 (Fig. 6H-N), when fibrosis was already established. 
Imatinib significantly reduced renal fibrosis and renal elastin expression (Fig. 6H,I,L,N). 
MRI signal intensities obtained in imatinib-treated mice were significantly lower than 
control mice, and signal intensities resembled treatment efficacy (Fig. 6J,K,M; fig. S12B).  
Molecular imaging of renal fibrosis vs. analyses of kidney function 
Finally, we investigated whether elastin imaging can detect renal fibrosis more 
sensitively and more precisely than routine clinical biomarkers for assessing kidney 
function (serum creatinine, creatinine clearance). We used a reversible model of adenine 
nephropathy in which the animals were left to recover for 14 days after an initial disease 
induction period of 14 days (Fig. 7A). Although renal function normalized in the recovery 
phase (Fig. 7B-E), renal fibrosis persisted, and elastin remained increased (Fig. 7H-J). 
This exemplifies that functional recovery of kidney function (via hyperfiltration by 
remaining intact nephrons) differs from persistent morphological damage (Fig. 7F-J). 
Elastin imaging accurately captured the remaining pathological features and the 
persistence of fibrosis, as exemplified by the similarly high levels of signal intensity after 
2 weeks of adenine diet and after 2 weeks of terminating the diet (Fig. 7K-M, fig. 
S13A,B). Gadolinium quantification via ICP-MS supported this conclusion (fig. S13C). 
Overall, these findings demonstrate the potential of elastin imaging for diagnosis, staging 
and treatment monitoring of kidney fibrosis.  
 
Discussion 
We showed that elastin expression can be non-invasively visualized and quantified using 
ESMA-based molecular MRI for renal fibrosis assessment. This allows for fibrosis 
staging and for more accurate and specific monitoring of anti-fibrotic therapy compared 
to current clinical biomarkers, like GFR. Our studies showed that elastin is a suitable 
target for molecular imaging and kidney fibrosis monitoring using 10 animal models and 
more than 140 patient samples, covering all major renal diseases (24, 25). Elastin was 
largely absent in healthy kidneys, dynamically upregulated in fibrotic kidneys, and its 
expression increased independently of the underlying disease trigger, suggesting a 
broad applicability of elastin as a marker for assessing disease progression in CKD. 
Elastin expression specifically reflects renal fibrosis, which is not captured by current 
renal function parameters, in particular GFR measurement. Mechanistically, using 
multiple experimental setups, we showed that in renal fibrosis PDGFR-β+ resident 
(myo)fibroblasts are the main elastin producing cells. Blocking PDGFR signaling using 
imatinib reduced elastin expression, whereas stimulation of renal fibroblasts with PDGF 
induced elastin expression, together strongly suggesting that PDGF plays a key role in 
the regulation of elastin expression in kidney fibrosis.  
Non-invasive imaging has gained widespread attention for fibrosis assessment, 
especially in cardiovascular, liver, and lung fibrosis (8, 13). For kidney fibrosis, however, 
no imaging probes or protocols are available (10, 12, 26, 27). This severely complicates 
clinical trial design in kidney fibrosis and CKD because there are no clinical endpoints 
available (apart from proteinuria and decline of GFR) that can specifically reflect therapy 
effects, particularly when patients are treated with anti-fibrotic drugs. Functional imaging 
based on ultrasonography and MR elastography is extensively used to stage liver 
fibrosis (28, 29), but both modalities are unsuitable for specifically assessing kidney 
fibrosis (10, 11, 30). Functional diffusion-weighted MRI has also been tested for renal 
fibrosis monitoring (31, 32), but was found to be unspecific, predominantly reflecting 
renal function and perfusion rather than renal fibrosis (12). Progress has been made in 
specific molecular imaging of fibrotic diseases in preclinical models with collagen-binding 
probes, which have shown promise for assessing liver and lung fibrosis (33, 34). Their 
potential for specifically visualizing and quantifying renal fibrosis, however, could be 
limited because of the high basal expression of collagens in the kidneys. Together, these 
insights underline the importance of carefully considering not only imaging probes and 
protocols, but also organ-specific differences in biomarker expression, anatomy, and 
function, as well as their dynamic alterations during fibrosis initiation, progression, and 
regression. 
Several issues have to be considered for clinical translation of ESMA-based molecular 
imaging of renal fibrosis. First, specifically designed clinical trials will be required to 
prove that the imaging information obtained using ESMA-enhanced MRI corresponds 
with histologically assessed elastin expression in the kidneys, reflects disease stage 
(and/or disease progression), and can monitor treatment responses. Our expression 
analyses of elastin in a large set of renal biopsies of CKD patients and our ex vivo 
incubation studies with ESMA in healthy and fibrotic human kidney tissues provide a 
sound basis for such future clinical trials. Second, the potential risk of inducing 
nephrogenic systemic fibrosis as a result of using a gadolinium-based contrast agent in 
CKD has to be considered. Thus far, this complication is limited to dialysis patients or to 
patients with very advanced stages of CKD (stage 5). In CKD stage 5, elastin imaging is 
unlikely to be of clinical use. In less advanced CKD stages, in which fibrosis follow-ups 
would be clinically useful, the repetitive administration of gadolinium-based contrast 
agents is generally considered to be safe (35). Nonetheless, as an alternative, the 
labeling of ESMA with radioisotopes, such as 68Ga or 111In could be explored. This would 
allow for molecular imaging of renal fibrosis via Positron Emission Tomography (PET) 
and Single Photon Emission Computed Tomography (SPECT) imaging, and would 
resolve potential safety concerns associated with the use of gadolinium-containing 
contrast agents.  
In summary, we showed that ESMA-based molecular MRI allows for non-invasive, 
quantitative and longitudinal assessment of renal fibrosis and fibrosis regression. We 
demonstrated that ESMA-based molecular MRI can be used for treatment monitoring, 
and that it more faithfully reflects fibrosis than current clinical standards. We propose 
that elastin imaging may be a robust, fibrosis-specific diagnostic tool and useful 
surrogate endpoint for clinical studies evaluating the efficacy of anti-fibrotic therapies.  
Materials and methods 
Study design 
We hypothesized that elastin could serve as a target for kidney fibrosis, for non-invasive 
longitudinal molecular imaging, and for monitoring as well as quantification of kidney 
fibrosis. We first comprehensively assessed and validated elastin as a fibrosis biomarker 
in human, murine and rat tissues. Next, in multiple murine models of renal fibrosis, we 
analyzed the potential of elastin-based molecular MRI for staging and treatment 
monitoring of renal fibrosis (fig S14). 
Animal experiments were performed in accordance with the guideline for care and use of 
laboratory animals and were approved by the local review boards and authorities. All 
animals were randomly assigned to treatment and imaging groups. 
Human kidney samples from nephrectomy specimens from the Institutes of Pathology 
and the centralized biomaterial bank were obtained and processed in an anonymous 
manner, the study was approved by the local review boards of Aachen and Erlangen 
(EK042-17, EK244-14, EK206-09, Re.-No.4415) and in line with the Declaration of 
Helsinki. 
All analyses were performed in a strictly blinded manner. 
Statistical analysis 
All data are presented as mean ± SD. Human data on quantification of elastin 
expression are presented as median ± range. A two-tailed unpaired Student’s t test was 
applied for comparison of continuous variables between two groups; the Mann–Whitney 
U test was used when data were non-normally distributed. One-way analysis of variance 
(one-way ANOVA) followed by the Bonferroni test was used for comparison of >2 groups. 
The paired t test was used for comparing the fibrotic and contralateral kidneys in one 
animal. Statistical significance was defined as P < 0.05. All statistical analyses were 
performed using GraphPad Prism 6.0. 
 
Animal experiments 
Animals were housed under standard conditions (SPF-free) and kept in an environment 
with constant temperature and humidity under a 12-hour phase light-dark cycle. Drinking 
water (ozone-treated and acidified) and food were freely available. All surgeries were 
performed under anesthesia by ketamine (14 g/kg body weight) and xylazine (8 g/kg 
body weight). Analgesia with Temgesic (0.05 mg/kg) was used until 72 h post OP. 
During the surgical period, body temperature was maintained between 35°C and 37.5°C 
using a temperature-controlled heating system. Every effort was made to minimize 
animal suffering. Animals were sacrificed by overdose of isoflurane or by exsanguination. 
The murine kidneys were collected after transcardial perfusion with 50 ml of 
physiological saline.  
Four rat and six mouse models were used in the study characterizing elastin expression 
in fibrosis. These included the unilateral ureteral obstruction (UUO) model in Wistar rats 
(day 7; n = 4), the chronic anti-Thy 1.1 nephritis in Wistar rats (day 56; n = 4), the 5/6 
nephrectomy model in Fisher 344 rats (week 20, n = 4), and the adenine nephropathy 
model in Fisher 344 rats (week 4, n = 4) (6, 14, 36). Rats were bought from Charles 
River (Erkrath or Sulzfeld, Germany). Mouse models included: UUO, conducted in 10 
week-old C57BL/6N mice, with kidneys from both obstructed and contralateral sides 
harvested at day 1, 3, 5, 7, 10, 14, 21 after UUO (n = 5 each time point). Sham group 
were used as control (n = 4) (15, 26). I/R (ischemia-reperfusion injury) was performed in 
C57BL/6N mice, kidneys were harvested on day 1, 3, 5, 7, 10, 14, 21 after I/R (n = 4 
each time point). Sham group was used as control (n = 4) (26). Adenine nephropathy 
was induced in 10 week-old C57BL/6N mice by feeding 0.2% adenine diet. Kidneys 
were harvested on day 1, 3, 5, 7, 14, 21 (n = 4 each time point), day 1 healthy mice were 
used as control (n = 4) (15). Alport mice (Col4a3-/-) on 129/SvJ background were 
analyzed at 4 (n = 4) and 8 weeks (n = 5) of age; and wild-type littermates of eight 
weeks (n = 5) were used as control (15, 26). Folic acid nephropathy (FAN) was induced 
in 10 week-old C57BL/6N mice by weekly i.p. injection of folic acid (250 mg/kg of body 
weight and dissolved in NaHCO3). Mice were euthanized after 8 weeks. The model of 
nephrotoxic serum nephritis (NTN) was induced in 13 week-old male C57BL/6N mice by 
a single i.p. injection of 750 µl NTS and 40 µg CpG-oligonucleotide. 
For in vivo imaging studies in renal fibrosis, UUO (n = 8), I/R (n = 8) and adenine 
nephropathy (n = 8) were used. Healthy mice were used for control (n = 8) in adenine 
nephropathy group. Contralateral kidneys were used as control in UUO and I/R groups. 
The I/R model was used to proof in vivo specificity of ESMA in a competition experiment. 
On day 21 mice (n = 4) were injected i.v. with 25-fold dose of 69Ga-ESMA (5 mmol/kg 
bodyweight), 4 h prior to the standard 153Gd-ESMA injection (0.2 mmol/kg bodyweight).  
69Ga is a stable gallium isotope that is MR transparent. Control mice (n = 4) received 
only the standard 153Gd-ESMA injection. MRI was performed 4 h and 24 h after 
153Gd-ESMA injection. 
The model of adenine nephropathy was also used to study pharmacokinetics of ESMA 
(n = 4). MRI was performed before, 24 hours, 48 hours and 72 hours after ESMA 
injection on day 0, day 14 and day 21.To investigate whether ESMA can monitor 
therapeutic effects on renal fibrosis, mice with adenine nephropathy were treated with an 
inhibitor of the NLRP3 and AIM2 inflammasomes (CRID3, 0.2 µg/g i.p daily) from day 0 
of adenine diet (n = 3). Previously, CRID3 was shown to significantly decrease renal 
fibrosis in this murine model (23). MRI was performed before and 24 h after ESMA 
injection on day 21. 
The I/R model was also used to assess applicability of ESMA to monitor effects of an 
anti-fibrotic therapy. From day 7 until day 21 I/R mice either received the tyrosine-kinase 
inhibitor Imatinib (50 mg/kg in H2O, given daily via oral gavage, daily, n = 8) or normal 
H20 as vehicle control (n = 8). MRI was performed before and 24 h after ESMA injection. 
The adenine reversal model was induced by feeding mice for 14 days with adenine food 
and subsequent 14 days of normal food. MRI was performed before and 24 hours after 
ESMA injection on day0, day14 and day21.The adenine recovery experiment (n = 8) 
was designed to investigate the in vivo imaging possibilities in regard to evaluate renal 
fibrosis in comparison to renal function examination. 
MRI acquisition 
The elastin-specific molecular imaging agent ESMA is a low molecular weight 
(855.95 Da) combination of 153Gd-DTPA to D-amino acid D-phenylalanine, which was 
previously extensively characterized to specifically bind elastin. Unbound ESMA has a 
longitudinal relaxivity of 4.7 ± 0.1 mM−1 s−1, elastin-associated ESMA has a relaxivity of 
8.7 ± 0.4 mM−1 s−1 at 3T (18). 
MRI was performed on a 3.0 T clinical MR imaging system (Achieva 3.0 T TX, Philips 
Healthcare, Best, The Netherlands) equipped with a standard clinical gradient system 
(30 mT/m, 200 mT/m per millisecond) (12). A specialized 3 T solenoid mouse coil Rx of 
127.728 MHz was used (Philips Medical System International B. V., Amsterdam, The 
Netherlands). All MRI scans were performed under free-breathing conditions without 
cardiac or respiratory-trigger gating system. Mice received anesthesia with isoflurane 
(1.5-2%) and were imaged in prone position. 
MR scanning was performed prior to, 4 h and 24 h after contrast agent injection. Imaging 
paradigm involved a series of baseline images; the imaging protocol involved scout 
sequence, T1-weighted TSE (turbo spin echo) sequence, T2-weighted TSE sequence, 
T1-weighted inversion recovery TFE (turbo field echo) sequence as well as T1 
relaxometry measurements. MRI was performed to achieve contrast-enhanced signal or 
R1 value 24 h after a bolus i.v. injection of contrast agent of ESMA or Gd-DTPA via tail 
vein. ESMA was diluted in 100 µl physiologic saline. Commercially available unspecific 
Gd-DTPA was bought from Bayer Pharma AG (Magnograf, Berlin, Germany) and used 
as control. Both ESMA and Gd-DTPA were used in the same concentration of 
0.2 mmol/kg bodyweight.  
For the gelatin embedded human biopsy samples the MR scanning procedure included 
scout sequences, T1 weighted TSE (turbo spin echo) sequence as well as T1 
relaxometry measurements. 
T1-weighted TSE images were acquired with the following parameters: 
TR/TE = 500/20 ms, slice thickness = 0.7 mm, field-of-view (FOV) = 84 mm, 
WFS (pix) / BW (Hz) = 1.694/256.4, slices = 10, total scan duration ≈ 9 min. T2-weighted 
TSE images were acquired with the following parameters: TR/TE = 2000/100 ms, slice 
thickness = 1 mm, FOV = 84 mm, WFS (pix) / BW (Hz) = 1.705/254.08, and slices = 9, a 
total scan duration ≈ 7 min. T1-weighted inversion recovery TFE sequence parameters: 
TR/TE/TI = 27/8/500 ms, slice thickness = 0.5 mm, FOV = 30 mm, NSA = 2, Act. WFS 
(pix) / BW (Hz) = 12.430/35.0, Echoes = 1, flip angle = 30° and slices = 9, total scan 
duration ≈ 20 min. T1 relaxometry sequence: TR/TE = 6.5/3.4 ms, slice 
thickness = 1 mm, FOV = 42 mm, flip angle = 30°, TFE shots = 60, prepulse inversion 
time = 280ms, phase interval = 400ms, NSA = 1, Act. WFS (pix) / 
BW (Hz) = 1.126/385.8, and slices = 16, with a total scan duration ≈ 6 min. For the R1 
map an exponential curve beta*abs(0.5-exp(-R1*t)) was fitted to the voxel intensities 
over time. 
Image analysis 
MRI image analysis was done by using Imalytics Preclinical 2.0 (version 2.0.3.6) 
developed by Gremse-IT (Aachen, Germany). To obtain the signal intensity of kidneys in 
T1-weighted TSE images, MRI images were processed with the Imalytics Preclinical 2.0 
software in order to select ROIs manually in the cortex and medulla of each kidney 
separately according to the scheme shown in Supplementary Fig. 2. Two scientists (M.B. 
a PhD candidate with 3 years of experience of molecular imaging research, Q.S. a 
radiologist with 10 years of experience of clinical radiology) performed and quantified 
MRI measurements in a strictly blinded manner. 
CNR was calculated according to equation: CNR = (ROI - muscle signals)/noise. Muscle 
signal was determined in erector muscle of spine. Noise was determined as the standard 
deviation (SD) of the air lateral to kidneys.  
To measure R1 value via T1 relaxometry, ROIs were manually placed over the cortex 
and medulla area of each kidney. The visible differentiation of cortex and medulla was 
based on the knowledge of renal morphology and histology and supported by the T1 and 
T2-weighted images. Cortex and medulla were not possible to be separately analyzed in 
the UUO kidneys due to advanced parenchymal atrophy. ROI segmentation was drawn 
and saved, and loaded when T1 relaxometry was opened with Imalytics Preclinical 2.0 
software, the R1 value for selected ROIs were calculated via the fitting of an exponential 
curve beta*abs(0.5-exp(-R1*t)) to the voxel intensities over time and exported as Excel 
files. ∆CNR and ∆R1 were calculated via value post- minus pre - contrast agent injection. 
Human renal tissues 
Six non-fibrotic (control) kidneys (age 44 – 62 years, 2 males, 4 females) and six fibrotic 
kidneys (age 49 – 74 years, 3 males and 3 females) due to chronic pyelonephritis (n = 3), 
obstructive nephropathy with hydronephrosis (n = 2) and nephrolithiasis (n = 1). Non-
fibrotic kidney tissues were obtained from tumor nephrectomies due to renal cell 
carcinomas from unaffected, tumor distant areas (n = 3) or nephrectomies due to 
traumatic injury (n = 2) as well as discarded transplant kidneys (n = 1). Kidney tissues 
were divided and directly snap frozen in liquid nitrogen for mRNA and Western blot 
analyses or processed for histological and immunohistochemical analyses using 
standard procedures as described previously (15).  
For ex vivo MRI frozen kidney biopsy specimen were incubated for 1 h with ESMA or 
Gd-DTPA at room temperature. For both ESMA and Gd-DTPA the same concentration 
of 0.2 mmol/kg was used in physiologic saline, equally to the applied concentration in the 
animal experiments. 3 washing steps in physiologic saline for 5 min followed, before all 
biopsy samples were embedded in 10% gelatin for MRI measurements. 
To comprehensively analyze the expression of elastin in different kidney diseases and 
different CKD stages, additional archival FFPE kidney tissues from the Institute of 
Pathology in Aachen and the Institute of Pathology in Erlangen were collected and 
stained. In total, 146 specimens were analyzed (12 patients described above, used for 
RT-qPCR, histology, Western blot and ex vivo MRI, plus additional 134 FFPE samples 
for histology only). Tables S1-S2 summarize the patient data. 
Histology, immunohistochemistry and immunofluorescence 
Tissue for light microscopy and immunohistochemistry was fixed in methyl Carnoy 
solution, paraffin-embedded and cut into 1-µm sections. Periodic acid-Schiff (PAS) 
staining was used to assess renal morphology as described previously. Collagen type I, 
III and IV (Southern Biotechnology Associates, Birmingham, AL, USA), α-SMA (Dako, 
Glostrup, Denmark), PDGFR-β (Abcam, Cambridge, MA, USA), Fibronectin (Merck 
Millipore, Darmstadt, Germany) were performed as described previously (6, 15, 16, 26). 
Immunohistochemistry and immunofluorescence staining against elastin (Abcam, 
Cambridge, MA, USA) was done as follows: after deparaffinization and rehydration, 
endogenous peroxidase activity was blocked with 3% H2O2 in distilled water for 10 min 
at room temperature. All sections were blocked using avidin-biotin blocking kit (Vector 
Laboratories, Burlingame, CA, USA). Polyclonal rabbit anti-elastin antibody (ab21610 for 
mouse and rat tissue or HPA018111 for human tissue) was purchased and used in a 
dilution of 1:500 and incubated for 2 h. Biotinylated secondary goat anti-rabbit IgG 
antibody (Vector Laboratories, Burlingame, CA, USA) with dilution 1:300 or donkey 
anti-rabbit IgG conjugated with Alexa 647 (Jackson ImmunoResearch Laboratories, 
West Grove, PA, USA) with a dilution 1:200 was incubated for 30 min. Nuclei were 
counterstained with methyl green for immunohistochemistry and DAPI for 
immunofluorescence. For negative controls, irrelevant isotype matched IgG or PBS were 
used instead of primary antibody, and no unspecific staining was observed for elastin 
(Supplementary Fig. 7) or other staining. All sections were analyzed with a Keyence 
BZ-9000 microscope (Osaka, Japan). 
The whole slides were fully digitalized using whole-slide scanner NanoZoomer 2.0-HT 
(Hamamatsu Photonics, Shizuoka Prefecture, Japan), and analyzed using imaging 
software NDP.view (Hamamatsu Photonics, Hamamatsu, Japan) and ImageJ (National 
Institutes of Health, Bethesda, MD, USA). The percentage of positively stained area in 
each tissue was analyzed separately in 16-20 fields of each cortex and medulla at 20x 
magnification, representing almost the entire whole kidney area as described previously 
(15, 16, 26). All analyses were performed in blinded manner. 
Elastin staining in cohorts of patient samples were scored as follows: 0: positive 
vasculature and eventually very few elastin spots in perivascular areas; 1: 
elastin-bundles accumulating around vessels; 2: larger areas of elastin-bundles around 
vessels & focal spots in the interstitium; 3: strong staining of larger areas with 
perivascular elastin-bundles & multiple focal spots in the interstitium; 4: massive 
elastin-bundles in the interstitium; 5: diffuse and strong elastin staining in more than 50% 
of the interstitium. 
RNA extraction and analysis 
Total RNA was extracted from murine and human kidneys, as well as NRK-49F cells as 
described previously (15, 16, 36). Cortex and medulla were separated using 
macro-dissection. RNA was extracted from mice or human kidneys, using the RNAeasy 
Mini Kit (Qiagen, Hilden, Germany), while RNA from cells was extracted using RNA Mini 
Kit (Stratec biomedical AG, Berlin, Germany) according to the manufacturer’s instruction. 
The concentration and the purity of RNA were measured spectrophotometrically using 
Nanodrop (NanoDrop Technologies, Wilmington, DE, USA). Complementary DNA was 
synthesized and real-time quantitative polymerase chain reactions were performed using 
SYBR Green Master Mix (Bio-Rad Laboratories B. V., Veenendaal, The Netherlands) as 
previously described (15, 16, 36). The Qiagen QuantiFast SYBR Green RT-PCR kit 
(Qiagen, Hilden, Germany) was used for quantitative real-time PCR according to the 
manufacturer’s instructions. All samples were analyzed in duplicates and all quantitative 
data from qRT-PCR were normalized to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). Sequences of primers are given in table S3. 
Western blot analysis 
Protein isolation from tissues or cells was done and the protein concentration was 
measured using BC-assay methods as described previously (36), in short: equal 
amounts of protein (25 µg) were denatured and loaded in each well and separated on a 
NuPAGE 4 – 12% Bis–Tris gel (Life Technologies, Novex, Carlsbad, CA, USA) under 
reducing conditions in running gel system (Life Technologies) with voltage of 150 V for 
about 1 h and 20 min in NuPAGE MES running buffer (Life Technologies). Afterwards, 
proteins were transferred from sodium dodecyl sulphate (SDS) gel to an Amersham 
Protran 0.45 µm nitrocellulose membrane (GE Healthcare, Buckinghamshire, UK), using 
the iBlot system (Life Technologies) for separation. Unspecific antibody binding was 
prevented by blocking for 1 h at room temperature with 5% non-fat milk powder in TTBS 
(triethanolamine-buffered saline /Tween-20). Blots were incubated with mouse 
anti-elastin monoclonal antibody (MAB2503, Millipore, Temecula, CA, USA) diluted 
1:500 in TTBS overnight at 4°C. After washing in TTBS four times, the blots were 
incubated with HRP-labeled horse anti-mouse antibody (Vector Laboratories, 
Burlingame, CA, USA) diluted 1:10,000 in TTBS for 30 minutes. Chemiluminescent 
signal was generated using lumi-light plus Western blotting substrate (Roche 
Diagnostics, Mannheim, Germany) and detected using AGFA imaging system (Curix 60 
printer, AGFA, Mortsel, Belgium). After chemiluminescent detection, GAPDH was 
performed on the same nitrocellulose blots as housekeeping protein, and ECL (Thermo 
Scientific, Pierce, Rockford, IL, USA) was used for signal detection. Density of the bands 
was measured using ImageJ software and normalized to healthy controls. 
Transmission electron microscopy 
Kidneys tissues were cut into small pieces (1mm x 1mm x 1mm) and fixed in Karnovsky 
solution at 4°C (sodium cacodylate 4.28 g + 10% paraformaldehyde 4 g + 25% 
glutaradehyde 20 ml with A. dest in total volume 210 ml). Before examination, kidney 
tissues were counterstained with 0.25% tannic acid (Mallinckrodt, Paris, KY, USA) in 0.1 
M Soerensen’s phosphate buffer (Merck, Darmstadt, Germany) for 24 hours at room 
temperature. According to standard protocols (37), ultrathin sections were stained with 
uranyl acetate and lead citrate (all EMS, Munich, Germany), and viewed and analyzed 
using a transmission electron microscope EM906 (Zeiss, Oberkochen, Germany). 
Microautoradiography 
ESMA was radiolabeled with carrier free sodium pertechnetate 99mTc (eluted from 
Ultra-TechneKow® FM). Briefly, 1 mol/l ESMA was dissolved in ultrapure water and the 
pH adjusted to 4.5. To this solution oxidant-free, sterile and non-pyrogenic sodium 
pertechnetate 99mTc containing 20 MBq were added to yield the radiolabeled 99mTc-
ESMA. Radiochemical yield and purity were estimated via instant thin layer 
chromatography (iTLC) with aceton as eluens (RCY > 90%). 
For microautoradiography, slides from FFPE murine fibrotic renal tissues (I/R day 21 and 
I/R day 28 as well as UUO day 10, n = 18) were deparaffinized and rehydrated with 
ultrapure water. The synthesized [99mTc]Tc-DTPA-ESMA as of now appearing in this 
publication as 99mTC-ESMA was applied to the tissue and the slides were incubated at 
room temperature for 2 h, then washed with water before being dehydrated by using 
70% EtOH, 90% EtOH, and 100% EtOH. For competition experiments the radioactive 
99mTc-ESMA was mixed with the standard 153Gd-ESMA at a ratio of 1:10 000 and the 
slides incubated and washed as described for the binding assay. For both experiments, 
incubation with 99mTc-ESMA and competition, the radioactivity was kept constant (0.6 
MBq/slide). After incubation, slides were dipped into photographic emulsion (Kodak 
Emulsion NTB-2, Scientific Imaging Systems, Eastman Kodak Company, Rochester, NY, 
USA) under dark room conditions. The slides were left to drain on an absorbent surface 
for 5 s and then left to stand in a vertical position for 1 h to allow the emulsion to set. For 
exposure all samples were stored in a light tight box for 10 days at -20°C. After this 
period, the slides were allowed to equilibrate at room temperature in a light tight box for 
30 - 60 min. Meanwhile, working stocks of developer, stop solution, and fix solution were 
prepared under darkroom conditions. The exposed samples were then placed in 
developer (D-19, Kodak) for 5 min, gently agitated every minute. Next, the slides were 
transferred to stop solution (A.dest.) for 30 s and then incubated in fix solution (Unifix, 
Kodak) for 10 min while being gently agitated. Finally, the slides were placed in tap 
water and washed for 15 min using a constant, gentle flow of water. For visualization of 
the nuclei an additional staining with hematoxylin was performed. 
Additional materials and methods can be found in supplementary material. 
 
Supplementary materials 
Materials and methods 
Fig. S1. Scheme of in vivo molecular MRI of renal fibrosis in three independent mouse 
models of renal fibrosis 
Fig. S2. Confirmation of increased elastin expression in renal fibrosis. 
Fig. S3. Elastin expression in murine models of renal fibrosis. 
Fig. S4. Identification of interstitial (myo-)fibroblasts as elastin-producing cells in fibrotic 
kidneys. 
Fig. S5. Resident fibroblasts express elastin. 
Fig. S6. Elastin expression in CKD patients. 
Fig. S7. Staining validation by means of non-specific secondary antibody and buffer 
control. 
Fig. S8. Feasibility assessment of different MRI sequences and measurement times. 
Fig. S9. Elastin imaging detects fibrosis in adenine nephropathy. 
Fig. S10. Elastin imaging detects renal fibrosis in I/R. 
Fig. S11. Elastin imaging detects renal fibrosis in UUO. 
Fig. S12. Molecular MRI captures therapy effects in renal fibrosis. 
Fig. S13. Molecular MRI analysis of renal fibrosis vs. routine measurement of kidney 
function. 
Fig. S14. Overall study and experimental design. 
 
Table S1. Collection of patient fibrotic kidney samples reflecting different kidney 
diseases. 
Table S2. IgA nephropathy patient cohort. 
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Fig. 1. Elastin expression is increased in renal fibrosis. (A) Representative elastin 
immunofluorescence staining in healthy and fibrotic kidneys (rat UUO model) (n=4). 
Quantification of the elastin+ area in the cortex is shown in the right panel. (B) Transmission 
electron microscopy of elastin in kidney blood vessel walls (arrow head). The region enclosed by 
the dashed box is shown at higher magnification in the middle panels. Discontinued and rigid 
elastin fibers (open arrow) can be seen in the interstitium between collagen bundles (asterisks) in 
renal fibrosis (right panel). (C) Time course study of elastin expression (protein and mRNA) using 
Western blot and qRT-PCR in the murine model of adenine nephropathy (n=4 for each time point). 
Scale bar: 50 µm. Elastin area: *P < 0.05, t test. Elastin protein and mRNA: *P < 0.05, #P < 
0.0001, one way- ANOVA test with d1. 
 
 
Fig. 2. Elastin expression in fibrotic human kidneys is increased independent of 
the disease etiology. (A) Immunohistochemistry and (B) Western blot analysis of elastin 
expression and (C) qRT-PCR for elastin in human biopsies from healthy (n=6) and fibrotic (n=6) 
kidneys. (D) Renal elastin expression in major renal pathologies (n=89). [T0: protocol time zero 
biopsy of transplanted kidneys; Nephrectomy: non-affected tissue from tumor resection; 
Membranous GN: membranous glomerulonephritis; Crescentic GN: crescentic glomerulonephritis 
including Pauci-immune glomerulonephritis and lupus nephritis; FSGS: focal segmental 
glomerulosclerosis; Rejection: acute and chronic antibody and T cell-mediated renal rejection; 
ACKD: acquired cystic kidney disease; ADPKD: autosomal dominant polycystic kidney disease]. 
Scale bar: 50 µm. *P < 0.05, †P < 0.01, ‡P < 0.001, #P < 0.0001, Elastin expression healthy 




Fig. 3. Elastin imaging reflects renal fibrosis in adenine nephropathy and 
corresponds to elastin content in human kidney samples. (A-G) Murine adenine 
nephropathy. (A) Coronal T1-weighted MR images and (B) pseudo color-coded images before 
and 24 h after i.v. injection of ESMA and Gd-DTPA in healthy (n=4) and adenine-induced fibrotic 
(n=4) kidneys. (C, D) Quantification of normalized MRI signal intensities in cortex and medulla of 
ESMA- and Gd-DTPA-injected mice with healthy and fibrotic kidneys. (E, F) Gd quantification in 
cortex and medulla of healthy and fibrotic kidneys. (G) Gd distribution by LA-ICP-MS in healthy 
and fibrotic kidneys of mice with ESMA or Gd-DTPA. (H-L) Human kidney fibrosis. (H) 
Representative T1WI images of gelatin-embedded human kidney biopsies after incubation with 
ESMA or Gd-DTPA. (I, J) Quantification of normalized MR signal intensities in ESMA- and Gd-
DTPA-incubated healthy (n=4) and fibrotic (n=4) kidneys. (K, L) Gd quantification is reflective of 
ex vivo binding of ESMA in healthy and fibrotic human kidneys. ∆CNR: ∆ contrast-to-noise ratio. 
*P < 0.05, †P < 0.01, ‡P < 0.001, #P < 0.0001, t test. 
 
 
Fig. 4. ESMA specifically binds to elastin in renal fibrosis. (A, B) Representative T1-
weighted MR images and quantification of normalized MRI signal intensities of kidneys in the I/R 
mouse model. Mice received either standard 153Gd-ESMA (control, n=4) or a pre-injection of a 25-
fold excess of 69Ga-ESMA followed by 153Gd-ESMA (competition, n=4). (C, D) 
Immunofluorescence and Western blot analyses of elastin expression in mice injected with 153Gd-
ESMA alone (control) or pre-injected with a 25-fold excess of 69Ga-ESMA (competition). (E) 
Quantification of collagen I and α-SMA expression in control and competition group. (F, G) 
Representative images and quantification of binding of radiolabeled 99Tc-ESMA to murine kidney 
sections (n=18) ex vivo. Arrowheads denote elastin expression in arteries in healthy kidneys and 
interstitium in fibrotic kidneys. Scale bar: 50 µm. ∆CNR: ∆ contrast-to-noise ratio. *P < 0.05, †P < 
0.01, ns: not significant, t test. 
 
 
Fig. 5. Elastin imaging enables longitudinal monitoring of fibrosis progression in 
mice with adenine diet-induced nephropathy. (A) Representative T1-weighted MR 
images in renal fibrosis before disease induction (week 0) as well as at the second and third week 
of adenine diet (n=4). Scans were acquired before (pre) and 24 h after injection of the contrast 
agents. (B, C) MR Signal quantification in the cortex and medulla 24, 48, and 72 h after ESMA 
injection. (D) Western blot analysis of elastin in healthy kidneys and kidneys with adenine 
nephropathy-related fibrosis. (E) Immunofluorescence images of elastin expression in healthy 
and fibrotic kidney (adenine day 23). ∆CNR: ∆ contrast-to-noise ratio. *P < 0.05 compared to 
week 0, t test. ‡P < 0.001, #P < 0.0001, t test.  
 
 
Fig. 6. Elastin imaging enables monitoring of anti-fibrotic therapy response. (A) 
Representative immunohistochemical and immunofluorescent staining of collagen I, α-SMA, and 
elastin in kidneys from vehicle (n=4) and CRID3-treated (n=3) mice with adenine-induced 
nephropathy. (B) Quantification of collagen I expression in the cortex of vehicle- and CRID3-
treated kidneys. (C) MR images of kidneys obtained 24 h after the i.v. injection of ESMA in 
vehicle- and CRID3-treated mice. (D-G) Quantification of the MRI signal intensities and protein 
expression in the cortex (D, E) and medulla (F, G) of vehicle- and CRID3-treated mice. (H) 
Immunohistochemical and immunofluorescent staining of collagen I, α-SMA, and elastin in water- 
(n=8) or imatinib-treated mice (n=8) after I/R-induced fibrosis. (I) Quantification of collagen I 
expression in the cortex of water- and imatinib-treated mice. (J) MR images obtained 24 h after 
ESMA injection in water- and imatinib-treated mice. (K-N) Quantification of the MRI signal 
intensities and protein expression in cortex (K, L) and medulla (M, N) of imatinib-treated vs. 
vehicle treated mice. Scale bar: 50 µm. ∆CNR: ∆ contrast-to-noise ratio. *P < 0.05, †P < 0.01, ‡P 
< 0.001, t test. Mann-whitney test in Elastin protein in CRID3 and ∆CNR in imatinib treated mice. 
 
 
Fig. 7. Elastin imaging identifies residual renal fibrosis that is not detectable using 
routine kidney function measurement. (A) Scheme of the adenine reversal experiment: 
after 14 days of adenine diet, the animals received normal chow for 14 days in a “regeneration” 
phase. Red triangles represent injection of contrast agents, blue and black arrows show MRI 
scanning before and 24 h after injection, respectively. (n=4 ESMA, n=4 Gd-DTPA) (B-E) Serum 
creatinine (B), serum urea (C), creatinine clearance (D) and systolic blood pressure (E) analyses 
before, during, and 14 d after terminating the adenine diet. (F-G) Representative 
immunohistochemical staining (F) and quantification of collagen type III expression (G) in the 
cortex before, during, and 14 d after terminating the adenine diet. (H-I) Immunofluorescent 
staining (H) of elastin fibers and their quantification (I) in kidneys before, during, and 14 days after 
terminating the adenine diet. (J) Analyses of elastin expression via Western blot analysis of 
kidney tissue before, during, and 14 d after terminating the adenine diet. (K) ESMA-based MR 
imaging and (L, M) quantification of the normalized MR signal intensities in cortex (L) and 
medulla (M) before, during, and 14 d after terminating the adenine diet. Scale bar: 50 µm. ∆CNR: 
∆ contrast-to-noise ratio. *P < 0.05, †P < 0.01, ‡P < 0.001, #P < 0.0001, ns: not significant, t test. 
















Supplementary data - Materials and methods 
Cell Culture 
Rat renal fibroblasts (NRK-49F) were purchased from DSMZ (Germany collection of 
microorganisms and cell cultures, Braunschweig, Germany). NRK-49F cells were 
expanded and cultured according to manufacturer’s instructions, using DMEM medium 
high glucose + 5% fetal calf serum (FCS) (Invitrogen, Paisley, Scotland) in 75 cm2 flask 
in 5% CO2 37°C incubator. Cells were starved with starving medium 
(RPMI 1640 + L-glutamine (Invitrogen, Paisley, Scotland)) when cells reached 70-80% 
confluence. Cells were stimulated by PDGF-BB (Sigma Aldrich, Deisenhofen, Germany) 
with concentration of 1, 10 and 50 ng/ml or by PDGF-DD (R&D Systems, Minneapolis, 
MN) with concentration of 10, 50 and 100 ng/ml. Then cells were collected 48 h after 
stimulation and subjected to various analyses. 
Single-cell RNA sequencing 
We reanalyzed the published data from Kramann et al. (17), which investigated 
PDGFRb+/CD45+ and PDGFRb+/CD45- sorted cells from day 10 UUO kidneys of 
C57BL/6N mice. The read count of 51,810 genes was measured by using STAR 
(STAR_2.5.3a) (38) and HTSeq (version 0.9.1) (39) from the fastq file provided by 
GSE112033 with mouse primary assembly GRCm38. In order to remove low-quality 
cells and genes, we filtered out cells for which both library sizes and number of genes 
was lower than three median absolute deviations in log-space of all cells. In addition, we 
removed cells for which the read count of mitochondrial genes occupied more than 20% 
of the library size of the cell. 
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Inductively coupled plasma mass spectrometry 
Elemental gadolinium quantification in kidneys was performed with inductively coupled 
plasma mass spectrometry (ICP-MS). Tissues (10-30 mg) were mineralized in digestion 
medium (1.5 ml HNO3 65% + 1.5 ml H2O2 + 1 ml IS (Rhodium (1 µg/ml)) for 45 min at 
room temperature and heated to 210°C for 15 min. Gadolinium was measured by ELAN 
DRC II (Perkin Elmer Life and Analytical Sciences, Shelton, CT, USA). To make sure 
that the instrument was clean and optimized, spectral interferences were checked and 
reduced or eliminated before measurement. Rhodium (1 µg/ml) was used as internal 
standard. A standard curve was generated over the internal standard. Measurement 
results were compared to the standard curves and gadolinium concentration was 
calculated and normalized to the weight of kidney tissue used for the analyses. 
Laser ablation inductively coupled plasma mass spectrometry  
Kidney samples were cryo-cut into slices of 30 µm thickness with a cryomicrotome 
CM3050S (Leica Biosystems, Wetzlar, Germany) on -18°C cryo-chamber temperature 
and -16°C object temperature, thaw-mounted onto adhesive Starfrost® microscope slide 
(Knittel Glass, Braunschweig, Germany), dried and stored at room temperature. Tissue 
sections were photographed at 4x magnification with a light microscope IX81 (Olympus, 
Hamburg, Germany) to position the image dimensions. The distribution of gadolinium 
and other elements in sections of kidney tissues were systemically scanned (line by line) 
with a focused laser beam by LA-ICP-MS Xseries 2 (Thermo Fisher Scientific, Bremen, 
Germany) directly connected with a Nd:YAG laser ablation unit NWR260 (New Wave, 
Fremont, CA, USA). Matrix-matched tissue standards with well-defined concentrations of 
gadolinium were used as reference. Images were generated from LA-ICP-MS data using 
a Microsoft Excel 2007-based software tool with user-defined functions in Microsoft 





Supplementary data - Figures 
 
Fig. S1. Scheme of in vivo molecular MRI of renal fibrosis in three independent 
mouse models of renal fibrosis. Upper panel: experimental design and confirmation of renal 
fibrosis by PAS and collagen I staining. Red triangles represent injection of contrast agents, blue 
and black arrows show MRI scanning before and 24 h after injection, respectively. In the 
competition experiment an additional orange triangle shows injection of 25-fold dose of 69Ga-
ESMA and dark blue arrow shows MRI scanning 4 h after injection of 153Gd-ESMA. Collagen I 
positive area % and kidney volume were quantified. Lower left panel: methodology to quantify 
normalized MRI signal intensities and R1 echo times with T1WI and T1 relaxometry measurement, 
respectively. Lower middle panel: ex vivo confirmation of elastin expression and Gd distribution. 
Lower right panel: proof of ESMA specificity by in vivo MRI and ex vivo microautoradiography 
competition experiments. PAS: Periodic acid-Schiff; IHC/IF: immunohistochemistry/fluorescence; 
EM: electron microscopy; LA-ICP-MS: laser ablation-inductively coupled plasma mass 





Fig. S2. Confirmation of increased elastin expression in renal fibrosis. (A) 
Immunohistochemical micrographs for elastin expression in UUO (n=4) and the anti-Thy 1.1 (n=4) 
rat model. (B, C) Quantification of elastin+ area confirms increased elastin in renal fibrosis. (D) 
Representative images of immunofluorescent elastin stainings in anti-Thy 1.1, 5/6 nephrectomy 





Fig. S3. Elastin expression in murine models of renal fibrosis. (A) 
Immunohistochemical staining shows interstitial elastin expression in mice with nephrotoxic 
serum nephritis (NTN day 14) and folic acid nephropathy (FA week 8) compared to healthy mice. 
(B-D) Western blot and qRT-PCR for elastin expression during progression of renal fibrosis in the 
(B) I/R mouse model (n=4 each time point), (C) UUO mouse model (n=5 each time point) and (D) 
Alport mouse model (n=4-5 each time point). Scale bar = 50 µm. *P < 0.05, †P < 0.01, ‡P < 0.001, 




Fig. S4. Identification of interstitial (myo-)fibroblasts as elastin-producing cells in 
fibrotic kidneys. Immunofluorescent staining of elastin (red) and various specific markers 
(green). Elastin is co-localized with interstitial fibrotic tissue (fibronectin, collagen (Col) type I, Col 
III), and interstitial myofibroblasts (α-SMA and Platelet-derived growth factor receptor beta 
(PDGFR-β)), but did not co-localized with Col IV. Boxed areas are enlarged in the right panel. 




Fig. S5. Resident fibroblasts express elastin. (A) Representative Western blot and 
quantification of elastin protein as well as mRNA in NRK-49F fibroblast cell line after stimulation 
with PDGF-BB (B, D) and PDGF-DD (C, E). Single cell RNA sequencing data from UUO day 10 
mice comparing resident myofibroblasts (PDGFR-β+/CD45-) and circulating myofibroblasts 
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(PDGFR-β+/CD45+) (F, G). Data are mean ± S.D and represent triplicate experiments. *P < 0.05, 





Fig. S6. Elastin expression in CKD patients. (A) Representative immunohistochemical 
micrographs from patients with various type of kidney disease. T0: protocol time zero biopsy of 
transplanted kidneys, Membranous GN: membranous glomerulonephritis, Crescentic GN: 
crescentic glomerulonephritis including Pauci-immune glomerulonephritis and Lupus nephritis, 
FSGS: focal segmental glomerulosclerosis, ACKD: acquired cystic kidney disease, ADPKD: 
autosomal dominant polycystic kidney disease. (B) Elastin expression is quantified in a cohort of 
patients with IgA nephropathy with different CKD stages (n=7-11). Scale bar = 250 µm. †P < 0.01, 
‡P < 0.001, one way-ANOVA test with T0 biopsy. 
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Fig. S7. Staining validation by means of non-specific secondary antibody and 
buffer control. Assessment of the specificity of the antibodies used for the histological 
evaluation with controls for non-specific binding of IgGs as secondary antibodies and PBS buffer 





Fig. S8. Feasibility assessment of different MRI sequences and measurement 
times. (A) Extreme motion artifacts are observed in T1-weighted inversion recovery turbo spin 
echo sequence. (B) T1 relaxometry measurement. (C, D) T1WI images at different time points 
after i.v. injection identify 24 h as the preferred time point for ESMA-based non-invasive 




Fig. S9. Elastin imaging detects fibrosis in adenine nephropathy. (A) Color-coded 
images after injection with ESMA and Gd-DTPA in healthy kidneys. (B, C) Western blot and 
quantification of elastin in cortex and medulla in healthy (n=8) and fibrotic (n=8) kidneys. (D) 
Immunofluorescent microphotographs depict elastin in renal fibrosis. (E, F) ∆R1 changes in 
adenine model (n=4 for each group). ∆CNR: ∆ contrast noise ratio. ‡P < 0.001, #P < 0.0001, t test. 
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Fig. S10. Elastin imaging detects renal fibrosis in I/R. (A) Coronal T1WI and (B) pseudo 
color-coded images after injection of ESMA (n=4) and Gd-DTPA (n=4) in contralateral and I/R 
injured fibrotic kidneys. (C, D) Quantification of normalized MR signal intensities in cortex and 
medulla show differences between the ESMA and Gd-DTPA group in contralateral and fibrotic 
kidneys. (E, F) Western blot quantification of elastin in cortex and medulla as well as (G) 
immunofluorescent staining of elastin in renal fibrosis. (H, I) Gd quantification reflects the binding 
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of ESMA in fibrotic kidneys. (J) Gd distribution by LA-ICP-MS shows Gd accumulation in fibrotic 
kidneys in the ESMA group. (K, L) ∆R1 changes in I/R model. Ctrl: contralateral. Scale bar, 50 
µm. ∆CNR: ∆ contrast-to-noise ratio. *P < 0.05, †P < 0.01, ‡P < 0.001, #P < 0.0001, ns: not 





Fig. S11. Elastin imaging detects renal fibrosis in UUO. (A) Representative coronal 
T1WI and (B) pseudo color-coded images after injection with ESMA (n=4) and Gd-DTPA (n=4) in 
contralateral and UUO induced fibrotic kidneys. Extreme extension of left pelvis makes cortex and 
medulla indistinguishable. (C) Quantification of normalized MR signal intensities in parenchymal 
area (cortex plus medulla). (D) Representative Western blot and quantification of elastin in 
contralateral and fibrotic kidneys and (E) representative microphotographs of 
immunofluorescence of elastin in renal fibrosis. (F) Gd quantification reflects the binding of ESMA 
in fibrotic kidneys. (G) ∆R1 changes in UUO model. (H) ∆CNR shows no difference in pelvis 
between ESMA and Gd-DTPA. Ctrl: contralateral. Scale bar, 50 µm. ∆CNR, ∆ contrast-to-noise 






Fig. S12. Molecular MRI captures therapy effects in renal fibrosis. 
(A) Representative MR images of adenine kidneys before ESMA injection and (B) I/R model on 




Fig. S13. Molecular MRI analysis of renal fibrosis vs. routine measurement of 
kidney function. (A) Representative MR images before injection of ESMA (n=4) and Gd-DTPA 
(n=4). (B) Quantification of normalized signal intensities of the cortex and medulla. (C) Gd 
quantification in both cortex and medulla of ESMA or Gd-DTPA injected kidneys. ∆CNR: ∆ 







Fig. S14. Overall study and experimental design. (A) Schematic depiction of the 
experimental setup to analyze elastin expression and to assess its potential as an imaging 
biomarker for monitoring renal fibrosis. 
 
Table S1. Collection of patient fibrotic kidney samples reflecting different kidney 
diseases. FFPE kidney samples from 89 patients were included in the study [9x time-zero 
biopsies (T0, non-fibrotic control), 5x tumor nephrectomies (non-tumor tissue, non-fibrotic control), 
5 IgA nephropathy, 4x membranous nephropathy, 10x crescentic glomerulonephritis (GN, 
including 5x pauci-immune and 5x lupus nephritis), 5x focal segmental glomerulosclerosis 
(FSGS), 6 diabetic nephropathy (DN), 5x hypertensive nephropathy (HN), 3x renovascular 
disease, 7x interstitial nephritis, 14x transplant rejection (including acute and chronic, antibody 
and t-cell mediated), 6x hydronephrosis, 5x acquired cystic kidney disease (ACKD) and 5x 
autosomal dominant polycystic kidney disease (ADPKD)]. 
Disease Sex Age 
T0 (non-fibrotic control) M 55 
T0 (non-fibrotic control) M 66 
T0 (non-fibrotic control) M 70 
T0 (non-fibrotic control) M 55 
T0 (non-fibrotic control) M 43 
T0 (non-fibrotic control) F 70 
T0 (non-fibrotic control) M 67 
T0 (non-fibrotic control) M 53 
T0 (non-fibrotic control) M 67 
Nephrectomy M 77 
Nephrectomy M 54 
Nephrectomy F 3 
Nephrectomy F 47 
Nephrectomy n.a. n.a. 
IgA Nephropathy M 50 
IgA Nephropathy M 35 
IgA Nephropathy M 27 
IgA Nephropathy M 44 
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IgA Nephropathy M 36 
Membranous GN M 32 
Membranous GN M 25 
Membranous GN M 46 
Membranous GN M 39 
Crescentic GN (Pauci immune) F 65 
Crescentic GN (Pauci immune) F 74 
Crescentic GN (Pauci immune) F 45 
Crescentic GN (Pauci immune) F 78 
Crescentic GN (Pauci immune) F 59 
Crescentic GN (Lupus) F 41 
Crescentic GN (Lupus) M 55 
Crescentic GN (Lupus) F 19 
Crescentic GN (Lupus) F 68 
Crescentic GN (Lupus) F 40 
FSGS M 55 
FSGS M 36 
FSGS F 79 
FSGS M 47 
FSGS M 51 
DN M 46 
DN M 52 
DN F 46 
DN M 56 
DN M 37 
DN F 55 
HN M 51 
HN M 34 
HN M 56 
HN M 40 
HN M 71 
Renovascular disease M 47 
Renovascular disease M 70 
Renovascular disease M 72 
Interstitial nephritis M 68 
Interstitial nephritis M 89 
Interstitial nephritis M 63 
Interstitial nephritis F 46 
Interstitial nephritis F 43 
Interstitial nephritis M 5 
Interstitial nephritis F 16 
Rejection M 43 
Rejection F 58 
Rejection M 48 
 21
Rejection F 60 
Rejection F 50 
Rejection M 55 
Rejection F 20 
Rejection F 73 
Rejection M 43 
Rejection M 28 
Rejection M 50 
Rejection M 47 
Rejection M 35 
Rejection M 66 
Hydronephrosis F 47 
Hydronephrosis F 47 
Hydronephrosis M 78 
Hydronephrosis M 56 
Hydronephrosis M 55 
Hydronephrosis M 25 
ACKD M 56 
ACKD F 53 
ACKD M 40 
ACKD M 46 
ACKD M 52 
ADPKD M 40 
ADPKD M 41 
ADPKD M 41 
ADPKD M 40 
ADPKD M 63 
 
Table S2. IgA nephropathy patient cohort. Patients with IgA nephropathy and different 
stages of CKD (based on eGFR according to KDIGO). In total, 45 patients (8x CKD 1, 9x CKD 2, 
10x CKD 3, 11x CKD 4, and 7x CKD 5) were included. 
Disease eGFR CKD-Stage (KDIGO) 
IgA nephropathy 117 1 
IgA nephropathy 117 1 
IgA nephropathy 102 1 
IgA nephropathy 100 1 
IgA nephropathy 113 1 
IgA nephropathy 94 1 
IgA nephropathy 95 1 
IgA nephropathy 104 1 
IgA nephropathy 60 2 
IgA nephropathy 67 2 
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IgA nephropathy 85 2 
IgA nephropathy 79 2 
IgA nephropathy 78 2 
IgA nephropathy 65 2 
IgA nephropathy 86 2 
IgA nephropathy 76 2 
IgA nephropathy 62 2 
IgA nephropathy 45 3 
IgA nephropathy 41 3 
IgA nephropathy 41 3 
IgA nephropathy 32 3 
IgA nephropathy 34 3 
IgA nephropathy n.a. n.a. 
IgA nephropathy 50 3 
IgA nephropathy 42 3 
IgA nephropathy 57 3 
IgA nephropathy 44 3 
IgA nephropathy 23 4 
IgA nephropathy 24 4 
IgA nephropathy 23 4 
IgA nephropathy 15 4 
IgA nephropathy 25 4 
IgA nephropathy 15 4 
IgA nephropathy 27 4 
IgA nephropathy 29 4 
IgA nephropathy 20 4 
IgA nephropathy 28 4 
IgA nephropathy 28 4 
IgA nephropathy 14 5 
IgA nephropathy 15 5 
IgA nephropathy 9 5 
IgA nephropathy 6 5 
IgA nephropathy 9 5 
IgA nephropathy 11 5 








Gene Forward primer Reverse primer 
Mouse 
  
Eln TCTTGCTGATCCTCTTGCTCA GGATAATAGACTCCACCGGGAA 
Gapdh GGCAAATTCAACGGCACAGT AGATGGTGATGGGCTTCCC 
Rat   
Eln ATCGGAGGTCCAGGCATTG ACCAGCACCAACCCCGTAT 
Gapdh ACAAGATGGTGAAGGTCGGTG AGAAGGCAGCCCTGGTAACC 
Human   
ELN GCCATTCCTGGTGGAGTTCCTGGA ACCGCACCTGCAGACACTCCTAAG 
GAPDH AGCCACATCGCTCAGACACC GCGCCCAATACGACCAAA 
ELN: elastin, GAPDH: glyceraldehyde-3-phosphate dehydrogenase. 
